Globeimmune Inc (GBIM) 주가 예측

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The company has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.